LianBio jumps as cardiac drug gets breakthrough therapy tag in China

LianBio

15/02/2022 14:06

** China-focused biotechnology company LianBio's shares
 LIAN.O  jump more than 11% to $4.30 premarket after
experimental drug mavacamten gets breakthrough therapy
designation in China  urn:newsml:reuters.com:*:nGNX36YGqX
    ** Mavacamten is currently in a late-stage trial to treat
patients with obstructive hypertrophic cardiomyopathy, a
condition in which some heart muscles become abnormally thick
    ** Three of four brokerages rate the stock "buy" or higher,
while one has "hold"; their median PT is $22
    ** Up to Monday's close, stock had fallen 37% YTD

 (Reporting by Leroy Leo)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))